ArticleCancers2020

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Zhuo-Xun Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.